URL Pharma Revenue and Competitors
Estimated Revenue & Valuation
- URL Pharma's estimated annual revenue is currently $44.8M per year.
- URL Pharma's estimated revenue per employee is $251,815
Employee Data
- URL Pharma has 178 Employees.
- URL Pharma grew their employee count by -3% last year.
URL Pharma's People
| Name | Title | Email/Phone |
|---|
URL Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $43.2M | 192 | 8% | N/A | N/A |
#2 | $81.8M | 346 | 3% | N/A | N/A |
#3 | $11.7M | 58 | 0% | N/A | N/A |
#4 | $1011.8M | 5034 | -9% | N/A | N/A |
#5 | $44.8M | 178 | -3% | N/A | N/A |
#6 | $13.1M | 50 | -7% | N/A | N/A |
#7 | $16.5M | 82 | 41% | N/A | N/A |
#8 | $17.3M | 68 | -4% | N/A | N/A |
#9 | $67.9M | 402 | 30% | N/A | N/A |
#10 | $14.9M | 51 | -16% | N/A | N/A |
What Is URL Pharma?
URL Pharma is a leading specialty pharmaceutical company with fully integrated technology development, product development, manufacturing, and commercialization capabilities. We leveraged over 60 years of experience, as a generic pharmaceutical R&D and manufacturing company, to successfully transition into a growing, profitable, and technology driven proprietary branded pharmaceutical business.
keywords:N/A
N/A
Total Funding
178
Number of Employees
$44.8M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
URL Pharma News
... the pharma industry can respond robustly to the health crisis but at a cost that ... Web URL: https://www.businessmarketinsights.com/.
Nilesh Shah, MD, Kotak Mahindra AMC, in conversation with ET Now's Nikunj Dalmia at the Times Network India Economic Conclave during a panel...
... Merz Pharma, Medytox, Sanofi, Ipsen Pharma, Galderma, Revance Therapeutics Inc., ... Web URL: https://www.businessmarketinsights.com/.
Other Companies in Philadelphia
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $66.4M | 178 | 23% | N/A |
#2 | $43.1M | 178 | -6% | N/A |
#3 | $15M | 179 | 8% | N/A |
#4 | N/A | 179 | 3% | N/A |
#5 | $19.7M | 179 | -2% | N/A |